The neurobiology of schizophrenia: New leads and avenues for treatment

Current Opinion in Neurobiology

Volumn 20, Issue 6, 2010, Pages 810-815

  Bray, Nicholas J ^a   Leweke, F Markus ^b   Kapur, Shitij ^a   Meyer Lindenberg, Andreas ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; GLYCINE; METABOTROPIC RECEPTOR; NEUROLEPTIC AGENT; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE 10A INHIBITOR; RO 4917838; TRANQUILIZER; UNCLASSIFIED DRUG;

ADD ON THERAPY; COPY NUMBER VARIATION; DISC1 GENE; ENZYME INHIBITION; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HERITABILITY; HUMAN; MOLECULAR GENETICS; NEUROBIOLOGY; NEUROPHYSIOLOGY; NONHUMAN; NRGN GENE; NRXN1 GENE; PRIORITY JOURNAL; PSYCHOPATHY; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TCF4 GENE; ZNF804A GENE;

ANIMALS; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 78651433980     PISSN: 09594388     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.conb.2010.09.008     Document Type: Review

References (60)

1. Steen R.G., Mull C., McClure R., Hamer R.M., Lieberman J.A. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006, 188:510-518.
2. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987, 44:660-669.
3. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999, 122:593-624.
4. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 2009, 35:549-562.
5. Sullivan P.F., Kendler K.S., Neale M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003, 60:1187-1192.
6. O'Donovan M.C., Craddock N., Norton N., Williams H., Peirce T., Moskvina V., Nikolov I., Hamshere M., Carroll L., Georgieva L., et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008, 40:1053-1055.
7. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietiläinen O.P., Mors O., Mortensen P.B., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
8. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., Dudbridge F., Holmans P.A., Whittemore A.S., Mowry B.J., et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460:753-757.
9. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752. International Schizophrenia Consortium.
10. Williams H.J., Norton N., Dwyer S., Moskvina V., Nikolov I., Carroll L., Georgieva L., Williams N.M., Morris D.W., Quinn E.M., et al. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry 2010, [Epub ahead of print].
11. Craddock N., O'Donovan M.C., Owen M.J. Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or 'schizoaffective') psychoses. Schizophr Bull 2009, 35:482-490.
12. Ferreira M.A., O'Donovan M.C., Meng Y.A., Jones I.R., Ruderfer D.M., Jones L., Fan J., Kirov G., Perlis R.H., Green E.K., et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008, 40:1056-1058.
13. Athanasiu L., Mattingsdal M., Kähler A.K., Brown A., Gustafsson O., Agartz I., Giegling I., Muglia P., Cichon S., Rietschel M., et al. Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort. J Psychiatr Res 2010, 44:748-753.
14. Green E.K., Grozeva D., Jones I., Jones L., Kirov G., Caesar S., Gordon-Smith K., Fraser C., Forty L., Russell E., et al. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol Psychiatry 2009, [Epub ahead of print].
15. Norton N., Williams H.J., Owen M.J. An update on the genetics of schizophrenia. Curr Opin Psychiatry 2006, 9:158-164.
16. O'Dushlaine C., Kenny E., Heron E., Donohoe G., Gill M., Morris D., Corvin A. Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility. Mol Psychiatry 2010, The International Schizophrenia Consortium, [Epub ahead of print].
17. Walsh T., McClellan J.M., McCarthy S.E., Addington A.M., Pierce S.B., Cooper G.M., Nord A.S., Kusenda M., Malhotra D., Bhandari A., et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008, 320:539-543.
18. International Schizophrenia Consortium Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008, 455:237-241.
19. Xu B., Roos J.L., Levy S., van Rensburg E.J., Gogos J.A., Karayiorgou M. Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet 2008, 40:880-885.
20. Stefansson H., Rujescu D., Cichon S., Pietiläinen O.P., Ingason A., Steinberg S., Fossdal R., Sigurdsson E., Sigmundsson T., Buizer-Voskamp J.E., et al. Large recurrent microdeletions associated with schizophrenia. Nature 2008, 455:232-236.
21. Ingason A., Rujescu D., Cichon S., Sigurdsson E., Sigmundsson T., Pietiläinen O.P., Buizer-Voskamp J.E., Strengman E., Francks C., Muglia P., et al. Copy number variations of chromosome 16p13. 1 region associated with schizophrenia. Mol Psychiatry 2009, [Epub ahead of print].
22. McCarthy S.E., Makarov V., Kirov G., Addington A.M., McClellan J., Yoon S., Perkins D.O., Dickel D.E., Kusenda M., Krastoshevsky O., et al. Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet 2009, 41:1223-1227.
23. Kirov G., Rujescu D., Ingason A., Collier D.A., O'Donovan M.C., Owen M.J. Neurexin 1 (NRXN1) deletions in schizophrenia. Schizophr Bull 2009, 35:851-854.
24. Bray N.J. Gene expression in the etiology of schizophrenia. Schizophr Bull 2008, 34:412-418.
25. Brzózka M.M., Radyushkin K., Wichert S.P., Ehrenreich H., Rossner M.J. Cognitive and sensorimotor gating impairments in transgenic mice overexpressing the schizophrenia susceptibility gene Tcf4 in the brain. Biol Psychiatry 2010, 68:33-40.
26. Buonocore F., Hill M.J., Campbell C.D., Oladimeji P.B., Jeffries A.R., Troakes C., Hortobagyi T., Williams B.P., Cooper J.D., Bray N.J. Effects of cis-regulatory variation differ across regions of the adult human brain. Hum Mol Genet 2010, [Epub ahead of print] doi:10.1093/hmg/ddq380.
27. Millar J.K., Wilson-Annan J.C., Anderson S., Christie S., Taylor M.S., Semple C.A., Devon R.S., St Clair D.M., Muir W.J., Blackwood D.H., et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 2000, 9:1415-1423.
28. Chubb J.E., Bradshaw N.J., Soares D.C., Porteous D.J., Millar J.K. The DISC locus in psychiatric illness. Mol Psychiatry 2008, 13:36-64.
29. Pletnikov M.V., Ayhan Y., Nikolskaia O., Xu Y., Ovanesov M.V., Huang H., Mori S., Moran T.H., Ross C.A. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry 2008, 13. 173-86, 115.
30. Kvajo M., McKellar H., Arguello P.A., Drew L.J., Moore H., MacDermott A.B., Karayiorgou M., Gogos J.A. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc Natl Acad Sci 2008, 105:7076-7081.
31. Kamiya A., Kubo K., Tomoda T., Takaki M., Youn R., Ozeki Y., Sawamura N., Park U., Kudo C., Okawa M., et al. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat Cell Biol 2005, 7:1167-1178.
32. Meyer K.D., Morris J.A. Disc1 regulates granule cell migration in the developing hippocampus. Hum Mol Genet 2009, 18:3286-3297.
33. Mao Y., Ge X., Frank C.L., Madison J.M., Koehler A.N., Doud M.K., Tassa C., Berry E.M., Soda T., Singh K.K., et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 2009, 136:1017-1031.
34. Camargo L.M., Collura V., Rain J.C., Mizuguchi K., Hermjakob H., Kerrien S., Bonnert T.P., Whiting P.J., Brandon N.J. Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol Psychiatry 2007, 12:74-86.
35. Millar J.K., Pickard B.S., Mackie S., James R., Christie S., Buchanan S.R., Malloy M.P., Chubb J.E., Huston E., Baillie G.S., et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 2005, 310:1187-1191.
36. Kim J.Y., Duan X., Liu C.Y., Jang M.H., Guo J.U., Pow-anpongkul N., Kang E., Song H., Ming G.L. DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. Neuron 2009, 63:761-773.
37. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004, 36:131-137.
38. Datta S.R., McQuillin A., Rizig M., Blaveri E., Thirumalai S., Kalsi G., Lawrence J., Bass N.J., Puri V., Choudhury K., et al. A threonine to isoleucine missense mutation in the pericentriolar material 1 gene is strongly associated with schizophrenia. Mol Psychiatry 2010, 15:615-628.
39. Tomppo L., Hennah W., Lahermo P., Loukola A., Tuulio-Henriksson A., Suvisaari J., Partonen T., Ekelund J., Lönnqvist J., Peltonen L. Association between genes of Disrupted in schizophrenia 1 (DISC1) interactors and schizophrenia supports the role of the DISC1 pathway in the etiology of major mental illnesses. Biol Psychiatry 2009, 65:1055-1062.
40. Meyer-Lindenberg A., Nicodemus K.K., Egan M.F., Callicott J.H., Mattay V., Weinberger D.R. False positives in imaging genetics. Neuroimage 2008, 40:655-661.
41. Mier D., Kirsch P., Meyer-Lindenberg A. Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis. Mol Psychiatry 2010, 15:918-927.
42. Esslinger C., Walter H., Kirsch P., Erk S., Schnell K., Arnold C., Haddad L., Mier D., Opitz von Boberfeld C., Raab K., et al. Neural mechanisms of a genome-wide supported psychosis variant. Science 2009, 324:605.
43. Meyer-Lindenberg A.S., Olsen R.K., Kohn P.D., Brown T., Egan M.F., Weinberger D.R., Berman K.F. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch Gen Psychiatry 2005, 62:379-386.
44. Wessa M., Linke J., Witt S.H., Nieratschker V., Esslinger C., Kirsch P., Grimm O., Hennerici M.G., Gass A., King A.V., et al. The CACNA1C risk variant for bipolar disorder influences limbic activity. Mol Psychiatry 2010, [Epub ahead of print].
45. Erk S., Meyer-Lindenberg A., Schnell K., Opitz von Boberfeld C., Esslinger C., Kirsch P., Grimm O., Arnold C., Haddad L., Witt S.H., et al. Brain function in carriers of a genome-wide supported bipolar disorder variant. Arch Gen Psychiat 2010, 67:803-811.
46. Altier C., Spaetgens R.L., Nargeot J., Bourinet E., Zamponi G.W. Multiple structural elements contribute to voltage-dependent facilitation of neuronal alpha 1C (CaV1.2) L-type calcium channels. Neuropharmacology 2001, 40:1050-1057.
47. van Gemert N.G., Joëls M. Effect of chronic stress and mifepristone treatment on voltage-dependent Ca2+ currents in rat hippocampal dentate gyrus. J Neuroendocrinol 2006, 18:732-741.
48. Meyer-Lindenberg A., Straub R.E., Lipska B.K., Verchinski B.A., Goldberg T., Callicott J.H., Egan M.F., Huffaker S.S., Mattay V.S., Kolachana B., et al. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest 2007, 117:672-682.
49. Tan H.Y., Nicodemus K.K., Chen Q., Li Z., Brooke J.K., Honea R., Kolachana B.S., Straub R.E., Meyer-Lindenberg A., Sei Y., et al. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest 2008, 118:2200-2208.
50. Zhang Y., Bertolino A., Fazio L., Blasi G., Rampino A., Romano R., Lee M.L., Xiao T., Papp A., Wang D., et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci 2007, 104:20552-20557.
51. Tost H., Braus D.F., Hakimi S., Ruf M., Vollmert C., Hohn F., Meyer-Lindenberg A. Acute D(2) receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits. Nat Neurosci 2010, 13:920-922.
52. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmüller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980, 20:379-382.
53. Fell M.J., Svensson K.A., Johnson B.G., Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 2008, 326:209-217.
54. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007, 13:1102-1107.
55. Javitt D.C. Glycine modulators in schizophrenia. Curr Opin Investig Drugs 2002, 3:1067-1072.
56. Black M.D., Varty G.B., Arad M., Barak S., De Levie A., Boulay D., Pichat P., Griebel G., Weiner I. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology (Berl) 2009, 202:385-396.
57. Tam G.W., van de Lagemaat L.N., Redon R., Strathdee K.E., Croning M.D., Malloy M.P., Muir W.J., Pickard B.S., Deary I.J., Blackwood D.H., et al. Confirmed rare copy number variants implicate novel genes in schizophrenia. Biochem Soc Trans 2010, 38:445-451.
58. Schmidt C.J., Chapin D.S., Cianfrogna J., Corman M.L., Hajos M., Harms J.F., Hoffman W.E., Lebel L.A., McCarthy S.A., Nelson F.R., et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 2008, 325:681-690.
59. Kehler J., Kilburn J.P. Patented PDE10A inhibitors: novel compounds since 2007. Expert Opin Ther Pat 2009, 19:1715-1725.
60. Leweke F.M., Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 2008, 13:264-275.